JAK2 and acute lymphoblastic leukemia: However, these agents had limited activity against mutant JAK2-expressing B-ALL cells, putatively due to paradoxical JAK2Y1007/1008 hyperphosphorylation mediated by these agents in these cells (Weigert et al. 2012; Wu et al. 2015).